HKSTP Crowns Overall Champion Skyland Innovation at EPiC 2023 Pitching Competition Beating Over 610 Global Startups
Hong Kong Science and Technology Parks Corporation (HKSTP) today successfully held its 7th Elevator Pitch Competition (EPiC), naming Hong Kong startup, Skyland Innovation, as the overall 2023 champion, beating over 610 startups from 55 economies around the world. The signature event has partnered with the city’s leading corporations: Cathay, HSBC, MTR Lab, plus global accelerator Plug & Play, to become a true iconic mega event that has hit a global scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230428005353/en/
Mr Albert Wong, CEO of HKSTP (Centre), alongside EPiC 2023 Top 10 overall finalists. (Photo: Business Wire)
As Hong Kong’s flagship and largest pitching contest, 50 Grand Finale semi-finalists joined the city’s most eagerly anticipated pitch event this year at sky100 at the top of the International Commerce Centre in West Kowloon to re-create a real-life 60-second elevator pitch experience.
The EPiC 2023 judging panel of the region’s top entrepreneurs, investors and innovation ecosystem leaders selected Skyland Innovation from Hong Kong, as this year’s overall champion. The winner of the grand prize of US$ 90,000, helps property owners and contractors to coordinate and communicate seamlessly on construction sites through the use of robotics and AI. The local proptech is also a spinoff from the Hong Kong Center for Construction Robotics (HKCRC) within the HKSAR Government backed AIR@InnoHK research cluster located at Hong Kong Science Park.
Along with all 50 semi-finalists, Skyland Innovation also qualifies to be considered by the HKSTP Venture Fund for additional investment deals. If selected, each company can potentially receive up to a maximum investment of US$5 million.
EPiC 2023 competitors were split across the two themes of FinTech and PropTech with FinCrime Dynamics from the UK named as the overall FinTech category winner, and Skyland Innovation Company Ltd named the overall PropTech winner from Hong Kong. This year, Canvasland, a FinTech startup from Hong Kong was also voted by the public as the “My Favourite Pitcher" winner, taking away US$10,000 and 200,000 Asia Miles. The top 10 overall finalists also won US$10,000 each (Full winners and finalists list below).
Paul Chan, Financial Secretary of Hong Kong SAR, said: “Hong Kong has a strong, thriving startup ecosystem with 4000 startups, up more than 50% from 2018. Hong Kong is also a natural gateway to the GBA, which offers tremendous growth opportunities. Successful products and services will surely have an edge in the GBA, the whole of the nation and around the world. I am truly excited to be here at EPiC 2023 where startups strive to make their 60-second pitch truly count. I congratulate all the EPiC 2023 winners and invite startups from all over the world to join us in Hong Kong where the future is built.”
Sunny Chai, Chairman, HKSTP, said: “EPiC 2023 showcases the most exciting innovations from the world’s star-studded next-generation global tech ventures. Together with the Hong Kong Government's solid commitment, as reinforced by the Hong Kong I&T Development Blueprint, our city provides the ideal platform to expand into the vast Asian market. Hong Kong is also Asia’s world city and a bridge between the mainland and the world, making us a magnet for global innovation talent and enterprises.”
Albert Wong, CEO, HKSTP, said: “This year’s EPiC competition features a record international turnout and shows Hong Kong is truly back with a strong show of unicorns and soonicorns from around the world among this year’s finalists. But EPiC is more than just a competition, it is a prime example of Hong Kong’s unique ability to help startups grow fast and go beyond by providing a network of global investment opportunities and innovation talent to turn cutting-edge science, technologies, and ideas into game-changing solutions."
A magnet for global investors and innovation talent
EPiC 2023 surpassed all expectations, attracting over 610 entries from 55 countries and cities across five continents. Over 75% of contestants come from overseas, a record high proportion of overseas contestants and economies participation since 2016. Startups joining EPiC 2023 can fully leverage the largest I&T ecosystem in Hong Kong and HKSTP’s direct connections to over 1,000 investors and more than 300 corporate partners.
In addition to the EPiC final pitching contest, the 50 semi-finalists have also taken part in the "Grow Beyond Hong Kong" Immersion Programme. This exclusive 2-day programme ran from 25-26 April, immersed the EPiC 2023 semi-finalists directly into HKSTP’s innovation ecosystem. Participants will unlock growth opportunities through educational talks, business matching and networking with leading corporate partners and investors in our ecosystem.
Winners List:
|
Overall Champion |
Skyland Innovation Company Ltd. |
||
|
“My Favourite Pitcher” Winner |
Canvasland Limited |
||
|
FinTech Winner |
FinCrime Dynamics |
||
|
PropTech Winner |
Skyland Innovation Company Ltd. |
||
|
Top 10 Overall Finalists |
FinTech Finalists:
FinCrime Dynamics Homebase Ultipa VoiceAI Technologies
PropTech Finalists:
I2Cool Limited
Mimicrete VoltSafe, Inc. Skyland Innovation Company Ltd. |
Contestants Breakdown:
|
Category |
|
|
No. of applicants |
|
PropTech |
|
|
266 (43%) |
|
FinTech |
|
|
352 (57%) |
|
|
|
|
|
|
|
|
|
No. of applicants |
|
Overseas |
|
|
465 (75%) |
|
Hong Kong |
|
|
153 (25%) |
A record high proportion of overseas contestants and economies participation since 2016.
For more information on EPiC 2023, please visit: https://epic.hkstp.org/
About Hong Kong Science and Technology Parks Corporation
Hong Kong Science and Technology Parks Corporation (HKSTP) has for over 20 years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that is home to two unicorns and Hong Kong’s leading R&D hub with over 13,000 research professionals and over 1,300 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.
Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern INNOPARKs in Tai Po, Tseung Kwan O and Yuen Long. The three INNOPARKs are realising a vision of new industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.
Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.
More information about HKSTP is available at www.hkstp.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230428005353/en/
Contact information
Media Contact:
Hong Kong Science and Technology Parks Corporation
Betsy Leung
Tel: +852 2629 2300
Email: betsy.leung@hkstp.org
Edelman Public Relations
Lisa Tse
Tel: +852 3756 8632 / 6347 2009
Email: Lisa.Tse@edelman.com / Edelmanhkstppr@edelman.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom